TY - JOUR T1 - Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody–Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.220139 SP - jrheum.220139 AU - Chengyin Lv AU - Hanxiao You AU - Lingxiao Xu AU - Lei Wang AU - Fenghong Yuan AU - Ju Li AU - Min Wu AU - Shiliang Zhou AU - Zhanyun Da AU - Jie Qian AU - Hua Wei AU - Wei Yan AU - Lei Zhou AU - Yan Wang AU - Songlou Yin AU - Dongmei Zhou AU - Jian Wu AU - Yan Lu AU - Dinglei Su AU - Zhichun Liu AU - Lin Liu AU - Longxin Ma AU - Xiaoyan Xu AU - Yinshan Zang AU - Huijie Liu AU - Tianli Ren AU - Fang Wang AU - Miaojia Zhang AU - Wenfeng Tan Y1 - 2022/06/15 UR - http://www.jrheum.org/content/early/2022/10/10/jrheum.220139.abstract N2 - Objective Interstitial lung disease (ILD) is a common extramuscular complication contributing to significant morbidity and mortality in patients with dermatomyositis (DM) who are positive for antimelanoma differentiation–associated gene 5 antibody (anti-MDA5+). We conducted this study to investigate the association of anti-Ro52 antibodies with clinical characteristics and prognosis in patients with anti-MDA5+ DM. Methods We assessed a cohort of 246 patients with anti-MDA5+ DM. To calculate hazard ratios and 95% CIs for rapidly progressive ILD (RP-ILD) and death while controlling for potential confounders, variables selected by univariate Cox regression analysis were included in a multivariate Cox regression model with the stepwise forward-selection method. A 2-tailed analysis with P < 0.05 was considered to be statistically significant. Results A total of 246 patients with anti-MDA5+ DM were enrolled; 70 patients were male, and the patient group had an average age of 53.1 (12.4) years. Anti-Ro52 was present in 64.2% (158/246) patients. Patients with anti-MDA5+ DM who were positive for anti-Ro52 had a higher rate of RP-ILD (log-rank P < 0.001) and a higher mortality rate (log-rank P = 0.01). For patients with anti-MDA5+ DM who were positive for anti-Ro52, those with a short disease course and high inflammation were at increased risk of RP-ILD and death. The appearance of active rash was an independent protective factor of death. Conclusion Anti-Ro52 antibodies were highly prevalent in patients with anti-MDA5+ DM, and their coexistence correlated with a higher rate of RP-ILD and mortality. Patients with a short disease course, with increased inflammation, and without rash were more likely to have a poor prognosis. ER -